Trial Profile
Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARESS
- 30 Mar 2020 Results of subgroup analysis of three subgroups: immunocompromised group: n=214, complex medical disorders group: n=4283 and standard indications group: n=20506, assessing respiratory illness hospitalization and RSV-related hospitalization hazard ratios were published in the Pediatric Infectious Disease Journal
- 30 Nov 2018 Results (n=21,107) assessing risk of respiratory illness- and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SI), and those without increased risk (NR), published in the Clinical Infectious Diseases.
- 04 May 2018 Results (n=23,228) published in the European Journal of Clinical Microbiology and Infectious Diseases.